This product passed the WHO prequalification in 2018 and is the world's first drug for malaria prophylaxis in children approved for seasonal malaria chemoprevention (SMC).
Therapeutic Area: prophylaxis for malaria.
It is a global initiative and the "gold standard" for treatment of severe malaria. It passed the WHO prequalification in 2005, is the first-choice drug for severe malaria recommended by the WHO, and is known as an "anti-malarial miracle drug".
Therapeutic Area: treatment of severe malaria
First-line anti-TB drug indicated for the treatment of tuberculosis in combination with other anti-TB drugs (such as streptomycin, isoniazid, rifampicin and ethambutol). a product passed consistency evaluation.
First-line anti-tuberculosis drug indicated for the treatment of tuberculosis caused by mycobacterium tuberculosis in combination with other anti-tuberculosis drugs; also used for the treatment of tuberculous meningitis and atypical mycobacterial infections; a product passed consistency evaluation.
First-line antituberculosis drug indicated for the treatment of various types of TB, including tuberculous meningitis and other mycobacterium tuberculosis infections. The first isoniazid product passed consistency evaluation.
Second-line antituberculous drug and the essential therapeutic drug for treatment of drug-resistant tuberculosis by inhibiting the cell wall synthesis of mycobacterium tuberculosis; a required drug for short-course regimen for treatment of drug-resistant tuberculosis.
First-line drug for treatment of drug-susceptible tuberculosis; rifampicin with less hepatic impairment and higher bioavailability; achieving the therapeutic effect of 0.6 g of general rifampicin with only two capsules per time.
A drug recommended by WHO guidelines in standard treatment regimens for drug-susceptible tuberculosis; the only fixed-dose four-drug combination for tuberculosis treatment included in the WHO Model Lists of Essential Medicines; improved patient compliance; reduced drug resistance rate.
It has quality of brand name drug, and is a product under National Medical Insurance Class B; a confidence choice for monotherapy of mixed infection of aerobic bacteria and anaerobic bacteria; simple choice for prevention of surgical infection and perioperative infection; economical choice for empirical therapy of infection of ESBLs-producing bacteria.
It has quality of brand name drug, and is a product under National Medical Insurance Class B; it is recommended by many guidelines and consensus at home and abroad; it has a broad antibacterial spectrum, covering G+ bacteria, G-bacteria and anaerobic bacteria; it has good stability against ESBL enzymes, and has a low drug resistance rate clinically.
It is an original product with high brand awareness and the highest market share; it is a chemical drug with simple component and clear structure; it is a lyophilized powder preparation, with good stability, facilitating storage, transportation and use; post-marketing safety reassessment of more than 30,000 cases confirms the high safety of the product.
It is an original product under National Medical Insurance Class B; it is the first oral anti-HBV drug marketed in China; it has high safety, has strong antiviral ability, and is a classic drug for patients with chronic hepatitis B; long-term treatment with it can effectively improve liver tissue inflammation and delay the progress of chronic hepatitis B disease.
It is a China's national essential drug under National Medical Insurance Class A, and is included in the National Centralized Drug Procurement List; it is recommended by multiple guidelines at home and abroad; it is an antibacterial drug for unrestricted use, and an experience choice for treatment of various common infections.